MicroRNA-223 and miR-143 are important systemic biomarkers for disease activity in psoriasis

Journal of Dermatological Science

Volumn 75, Issue 2, 2014, Pages 133-139

  Løvendorf, Marianne B ^a,b   Zibert, John R ^b   Gyldenløve, Mette ^a   Røpke, Mads A ^b   Skov, Lone ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b LEO PHARMA A S   (Denmark)

Author keywords

Biomarker; Blood; MicroRNA; PBMCs; Plasma; Psoriasis

Indexed keywords

BIOLOGICAL MARKER; METHOTREXATE; MICRORNA; MICRORNA 103; MICRORNA 107; MICRORNA 128; MICRORNA 143; MICRORNA 16; MICRORNA 181D; MICRORNA 185; MICRORNA 197; MICRORNA 19B; MICRORNA 21; MICRORNA 22; MICRORNA 223; MICRORNA 23A; MICRORNA 23B; MICRORNA 24; MICRORNA 26A; MICRORNA 27A; MICRORNA 338 3P; MICRORNA 34A; MICRORNA 451; MICRORNA 486; MICRORNA 503; MICRORNA 573 3; MICRORNA 5P; MICRORNA 652; MICRORNA 93; UNCLASSIFIED DRUG; GENETIC MARKER; IMMUNOSUPPRESSIVE AGENT; MIRN143 MICRORNA, HUMAN; MIRN223 MICRORNA, HUMAN;

ARTICLE; BLOOD; BLOOD SAMPLING; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE MARKER; DISEASE SEVERITY; DOWN REGULATION; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PSORIASIS VULGARIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; CASE CONTROL STUDY; DNA MICROARRAY; FEMALE; GENE EXPRESSION PROFILING; GENETIC MARKER; GENETIC SCREENING; GENETICS; MALE; MIDDLE AGED; PREDICTIVE VALUE; PROCEDURES; PSORIASIS; RECEIVER OPERATING CHARACTERISTIC; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION PROFILING; GENETIC MARKERS; GENETIC TESTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; MICRORNAS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS; PSORIASIS; REAL-TIME POLYMERASE CHAIN REACTION; ROC CURVE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84902656162     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2014.05.005     Document Type: Article

References (51)

1. Lowes M.A., Suárez-Fariñas M., Krueger J.G. Immunology of psoriasis. Annu Rev Immunol 2014, 32:227-255.
2. Villanova F., Meglio P.D., Nestlé F.O. Biomarkers in psoriasis and psoriatic arthritis. Ann Rheum Dis 2013, 72(Suppl 2):104-110. 10.1136/annrheumdis-2012-203037.
3. Rashmi R., Rao K.S., Basavaraj K.H. A comprehensive review of biomarkers in psoriasis. Clin Exp Dermatol 2009, 34:658-663.
4. Enerbäck C. Soluble biomarkers in psoriasis. Eur J Dermatol 2011, 21(6):844-850.
5. Ambros V., Lee R.C., Lavanway A., Williams P.T., Jewell D. MicroRNAs and other tiny endogenous RNAs in C. elegans. Curr Biol 2003, 13:807-818.
6. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116(2):281-297.
7. Bartel D.P. MicroRNAs:target recognition and regulatory functions. Cell 2009, 136(2):215-233.
8. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008, 105:10513-10518.
9. Cortez M.A., Bueso-Ramos C., Ferdin J., Lopez-Berestein G., Sood A.K., Calin G.A. MicroRNAs in body fluids - the mix of hormones and biomarkers. Nat Rev Clin Oncol 2011, 8(8):467-477.
10. Chen X., Ba Y., Ma L., Cai X., Yin Y., Wang K., et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008, 18:997-1006.
11. Chim S.S., Shing T.K., Hung E.C., Leung T.Y., Lau T.K., Chiu R.W., et al. Detection and characterization of placental microRNAs in maternal plasma. Clin Chem 2008, 54:482-490.
12. Lawrie C.H., Gal S., Dunlop H.M., Pushkaran B., Liggins A.P., Pulford K., et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008, 141:672-675.
13. Reid G., Kirschner M.B., Zandwijk N.V. Circulating microRNAs: association with disease and potential use as biomarkers. Crit Rev Oncol Hematol 2011, 80:193-208.
14. Pritchard C.C., Kroh E., Wood B., Arroyo J.D., Dougherty K.J., Miyaji M.M., et al. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res 2012, 5(3):492-497.
15. Valadi H., Ekström K., Bossios A., Sjöstrand M., Lee J.J., Lötvall J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007, 9(6):654-659.
16. Zernecke A., Bidzhekov K., Noels H., Shagdarsuren E., Gan L., Denecke B., et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal 2009, 2(100):ra81. 10.1126/scisignal.2000610.
17. Vickers K.C., Palmisano B.T., Shoucri B.M., Shamburek R.D., Remaley A.T. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 2011, 13(4):423-433.
18. Arroyo J.D., Chevillet J.R., Kroh E.M., Ruf I.K., Pritchard C.C., Gibson D.F., et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A 2011, 108(12):5003-5008.
19. Turchinovich A., Weiz L., Langheinz A., Burwinkel B. Characterization of extracellular circulating microRNA. Nucleic Acids Res 2011, 39(16):7223-7233.
20. Sonkoly E., Wei T., Janson P.C., Sääf A., Lundeberg L., Tengvall-Linder M., et al. MicroRNAs: novel regulators involved in the pathogenesis of psoriasis?. PLoS One 2007, 2(7):e610.
21. Zibert J.R., Løvendorf M.B., Litman T., Olsen J., Kaczkowski B., Skov L. MicroRNAs and potential target interactions in psoriasis. J Dermatol Sci 2010, 58(3):177-185.
22. Joyce C.E., Zhou X., Xia J., Ryan C., Thrash B., Menter A., et al. Deep sequencing of small RNAs from human skin reveals major alterations in the psoriasis miRNAome. Hum Mol Genet 2011, 20(20):4025-4040.
23. Ralfkiaer U., Hagedorn P.H., Bangsgaard N., Løvendorf M.B., Ahler C.B., Svensson L., et al. Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL). Blood 2011, 118(22):5891-5900.
24. Oyama R., Jinnin M., Kakimoto A., Kanemaru H., Ichihara A., Fujisawa A., et al. Circulating miRNA associated with TNF-a signaling pathway in Patients with plaque psoriasis. J Dermatol Sci 2011, 61:206-217.
25. Ichihara A., Jinnin M., Oyama R., Yamane K., Fujisawa A., Sakai K., et al. Increased serum levels of miR-1266 in patients with psoriasis Vulgaris. Eur J Dermatol 2012, 22:68-71.
26. Pivarcsi A., Meisgen F., Xu N., Ståhle M., Sonkoly E. Changes in the level of serum miRNAs in patients with psoriasis after antitumour necrosis factor-a therapy. British J Dermatol 2013, 169:563-570.
27. Smyth G.K., Speed T.P. Normalization of cDNA microarray data. Methods 2003, 31:265-273.
28. Gentleman R.C., Carey V.J., Bates D.M., Bolstad B., Dettling M., Dudoit S., et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004, 5(10):R80.
29. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc 1995, 57:289-300. series B.
30. Duttagupta R., Jiang R., Gollub J., Getts R.C., Jones K.W. Impact of cellular miRNAs on circulating miRNA biomarker signatures. PLoS One 2011, 6:e20769.
31. Allantaz F., Cheng D.T., Bergauer T., Ravindran P., Rossier M.F., Ebeling M., et al. Expression profiling of human immune cell subsets identifies miRNA-mRNA regulatory relationships correlated with cell type specific expression. PLoS One 2012, 7:e29979.
32. Zhang Y., Jia Y., Zheng R., Guo Y., Wang Y., Guo H., et al. Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin Chem 2010, 56:1830-1838.
33. Kim S.J., Dix D.J., Thompson K.E., Murrell R.N., Schmid J.E., Gallagher J.E., et al. Effects of storage, RNA extraction, genechip type, and donor sex on gene expression profiling of human whole blood. Clin Chem 2007, 1038-1045.
34. Cheng H.H., Yi H.S., Kim Y., Kroh E.M., Chien J.W., Eaton K.D., et al. Plasma processing conditions substantially influence circulating microRNA biomarker levels. PLoS One 2013, 8(6):e64795.
35. Feezor R.J., Baker H.V., Mindrinos M., Hayden D., Tannahill C.L., Brownstein B.H., et al. Whole blood and leukocyte RNA isolation for gene expression analyses. Physiol Genomics 2004, 19(3):247-254.
36. Häusler S.F.M., Keller A., Chandran P.A., Ziegler K., Zipp K., Heuer S., et al. Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening. Br J Cancer 2010, 103:693-700.
37. Simak J., Gelderman M.P. Cell membrane microparticles in blood and blood products: potentially pathogenic agents and diagnostic markers. Transfus Med Rev 2006, 20:1-26.
38. Nagalla S., Shaw C., Kong X., Kondkar A.A., Edelstein L.C., Ma L., et al. Platelet microRNA-mRNA coexpression profiles correlate with platelet reactivity. Blood 2011, 117(19):5189-5197.
39. Ciancio G., Ferracin M., Colina M., Zagatti B., Saccenti E., Seri M., et al. MicroRNA expression profile in peripheral blood cells of psoriatic arthritis. Clin Drug Invest 2013, 33(Suppl. 2):99-103.
40. Haneklaus M., Gerlic M., O'Neill L.A., Masters S.L. miR-223: infection, inflammation and cancer. J Intern Med 2013, 274(3):215-226.
41. O'Connell R.M., Zhao J.L., Rao D.S. MicroRNA function in myeloid biology. Blood 2011, 118(11):2960-2969.
42. Dorhoi A., Iannaccone M., Farinacci M., Faé K.C., Schreiber J., Moura-Alves P., et al. MicroRNA-223 controls susceptibility to tuberculosis by regulating lung neutrophil recruitment. J Clin Invest 2013, 123(11):4836-4848.
43. Dweep H., Sticht C., Pandey P., et al. miRWalk - database: prediction of possible miRNA binding sites by "walking" the genes of 3 genomes. J Biomed Inform 2011, 44:7-839.
44. Lee S.K., Jeon E.K., Kim Y.J., et al. A global gene expression analysis of the peripheral blood mononuclear cells reveals the gene expression signature in psoriasis. Ann Dermatol 2009, 21(3):237-242.
45. McKenna K.C., Beatty K.M., Vicetti Miguel R., Bilonick R.A. Delayed processing of blood increases the frequency of activated CD11b+ CD15+ granulocytes which inhibit T cell function. J Immunol Methods 2009, 341:68-75.
46. Hunter M.P., Ismail N., Zhang X., Aguda B.D., Lee E.J., Yu L., et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS One 2008, 3:e3694.
47. Tamagawa-Mineoka R., Katoh N., Kishimoto S. Platelet activation in patients with psoriasis: Increased plasma levels of platelet-derived microparticles and soluble P-selectin. J Am Acad Dermatol 2010, 62(4):621-626.
48. Takeshita J., Mohler E.R., Krishnamoorthy P., Moore J., Rogers W.T., Zhang L., et al. Endothelial cell-, platelet-, and monocyte/macrophage-derived microparticles are elevated in psoriasis beyond cardiometabolic risk factors. J Am Heart Assoc 2014, 3(1):e000507. 10.1161/JAHA.113.000507.
49. Ismail N., Wang Y., Dakhlallah D., Moldovan L., Agarwal K., Batte K., et al. Macrophage microvesicles induce macrophage differentiation and miR-223 transfer. Blood 2013, 121:984-995.
50. Ritchie M.E., Silver J., Oshlack A., Holmes M., Diyagama D., Holloway A., et al. A comparison of background correction methods for two-colour microarrays. Bioinformatics 2007, 23:2700-2707.
51. -δδCt method. Methods 2001, 25:402-408.